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Results: The follow up monitoring of members receiving these
mental health drugs demonstrated a signiﬁcant savings in phar-
maceutical expenditures with no adverse effect of total health
care expenditures or utilization. The measures employed (i.e.
prior authorization, stepped therapy, and co-pay differentials)
did not appear to adversely affect persistence with these med-
ications. Additionally, disenrollment from Medicaid due to incar-
ceration did not increase among this group of members during
the observation period.
Lessons Learned: The inclusion of mental health drugs in a phar-
macy beneﬁt design is a controversial effort. Allowing continu-
ation of established therapy and requiring members new to
therapy with these mental health agents to go through a prudent,
clinically appropriate process to utilize the most cost-effective
medication available has the potential to decrease the cost of
pharmaceuticals without adversely affecting the utilization of
other more costly health care resources. When embarking on the
inclusion of mental health medications in a pharmacy design
beneﬁt that includes prior authorization and step therapy, it is
imperative that stakeholders have complete understanding of 
the reason for inclusion, the process to assure access to neces-
sary medications, as well as feedback regarding the outcomes
measured.
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Organization: Premera Blue Cross Pharmacy and Therapeutics
Committee (P&T). Premera is a 1.6 million member regional
commercial health plan in the Paciﬁc Northwest of the U.S.
Problem or Issue Addressed: Need to determine formulary status
of Exenatide (Byetta), a recently marketed novel biologic agent
for the treatment of Type 2 Diabetes.
Goals: To test the usefulness of manufacturer-provided disease-
based cost-effectiveness models in helping formulary decision
makers to determine the value and appropriate place in therapy
for a new drug used to treat a chronic disease, when long-term
outcomes data for the new product are unavailable due to the
time required for long term sequelae of diabetes to be observed
in clinical trials.
Outcomes items used in the decision: Reduction in hemoglobin
A1c levels (A1c) and body mass index (BMI) observed in patients
receiving exenatide.
Implementation Strategy: Using the AMCP Format for Formu-
lary Submission (v2.1), Premera requested detailed information
from Amylin regarding the clinical and economic value of exe-
natide in a commercial health insurance population. Upon learn-
ing that Premera was requesting disease-based cost-effectiveness
modeling, Amylin purchased Web-based access to the CORE
Diabetes Model (CDM) for Premera staff. Amylin personnel
arranged training in the use of the model by CORE but no one
from Amylin participated in planning the modeling exercise,
choosing the input data and assumptions, or specifying the ana-
lytic scenarios. An informal Premera work group evaluated
various model scenarios and included a summary of the results
in the formulary recommendations to the P&T Committee.
Results: The model predicted reduced long-term treatment costs
in obese patients, driven by 11% decrease in cardiovascular
disease burden over a 30-year period. The incremental cost-effec-
tiveness ratio (ICER) for adding exenatide over 3 years was
$35,000/QALY. Using a 30-year horizon, ICER values were
$13,000/QALY versus insulin, $32,000 versus generic glyburide
and $16,000 versus no additional treatment. Exenatide domi-
nated pioglitazone. By comparison, the 30-year ICER for exe-
natide versus insulin in the non-obese cohort was $33,000. This
is a large longitudinal extrapolation based on relatively short
term trials, but it did help to conﬁrm the hypothesis that the drug
would beneﬁt a subgroup of obese patients. The P&T commit-
tee found this information useful and accepted staff recommen-
dation to add exenatide to formulary, with prior authorization
restrictions; however, due to limitations in the logistics of imple-
mentation, the restrictions did not limit use to obese patients.
Lessons Learned: Predicting long-term clinical outcomes of a
new drug from the results of short-term trials is challenging.
Good disease-based pharmacoeconomic models help payers
project costs, identify populations most likely to beneﬁt from
therapy, and perhaps craft restrictions that improve the poten-
tial for use of the drug in these populations, reducing the
numbers needed to treat and improving incremental cost-effec-
tiveness. In this context, a Format-compliant economic model
can facilitate communication between manufacturer and health
plan about the drug’s value.
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Organization: Alberta Province [A new evidence-based contin-
uum (referral to recovery) for hip and knee replacements was
piloted in Alberta within the Calgary Health Region, the David
Thompson Health Region and Capital Health Region.]
Problem or Issue Addressed: Redesigning an evidence based con-
tinuum for hip and knee replacements.
Bone and joint related conditions place a heavy burden on health
care systems and can signiﬁcantly impact patient quality of life.
As the population ages and new technologies are emerging, there
is profound concern about the sustainability of care for patients
with bone and joint related conditions. The demand for hip and
knee replacements is increasing due to changes in patient demo-
graphics (e.g., obesity) and an aging population. This increasing
demand coupled with the current burden on health care
resources and increasingly long wait times emphasized the
urgency for health reform.
Goals: The three participating regional health authorities
(Capital Health, Calgary Health Region, David Thompson
Health Region) in conjunction with the Alberta Bone and Joint
Health Institute and other partners designed and tested a new
evidence based continuum of care for hip and knee replacements.
The goals of this new continuum included signiﬁcant improve-
ment in the areas of access, quality and cost. This newly designed
continuum coordinated the patient’s journey from referral to
recovery. Standardized clinical paths, patient education and
accountability, clinic care teams, and dedicated operating rooms
and inpatient units were examples of how the continuum was
redesigned. To evaluate the new continuum, a randomized con-
trolled evaluation was applied to ensure robust results that
